Cefepime for Injection Vials Recalled Over Sterility Concerns
Cefepime for Injection vials are being recalled nationwide due to lack of sterility assurance. The product should not be used and affected individuals should contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable medication with confirmed lack of sterility assurance, which presents a risk of serious infection and harm. No illnesses, injuries, or deaths have been reported in the source text, making this a high-risk product without confirmed adverse events.
Plain-English summary
Cefepime for Injection, USP 2 grams per vial, is being recalled nationwide. Manufactured by Astral SteriTech Private Ltd. and distributed for Civica Inc., the product (NDC 72572-058-10) is affected by a lack of assurance of sterility. This means the manufacturer cannot confirm that the product meets required sterility standards for injectable medications.
All lots within their expiration dating are included in this recall, totaling 124,010 vials distributed nationwide. Injectable medications must maintain complete sterility to be safe for patient use.
Patients and healthcare providers who possess this product should not use it. Affected individuals should contact their healthcare provider for guidance regarding alternative treatments.
The recalled product
- Product
- Cefepime for Injection, USP 2 grams per vial, Rx only, Manufactured for: Civica Inc. Lehi Utah 84043, NDC 72572-058-10
- Manufacturer
- Astral SteriTech Private Ltd.
- Category
- Drug — Injectable / Antibiotic
- Hazard
- sterility-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01